Work

Efficacy of Immunotherapy in Treating Metastatic Melanoma: A Randomized Controlled Trial

Year: 2025

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Abstract: A BSTRACT Introduction: Immunotherapy has revolutionized the treatment of metastatic melanoma, offering prolonged survival and improved outcomes. Checkpoint inhibitors like PD-1/PD-L1 have demonstrated significant efficacy in modulating the immune system’s response to tumors. This randomized controlled trial aims to evaluate the efficacy of these therapies compared to standard care. Methods: A randomized trial was conducted on patients with advanced metastatic melanoma, who were assigned to either immunotherapy or traditional chemotherapy. Parameters included progression-free survival (PFS), overall survival (OS), and immune-related adverse events. Data analysis was conducted using appropriate statistical tests, with P values set at < 0.05 for significance. Results: Immunotherapy significantly improved PFS and OS compared to chemotherapy ( P < 0.01). Adverse events were manageable and consistent with the known profiles of checkpoint inhibitors. Conclusion: Immunotherapy provides a superior therapeutic option for patients with metastatic melanoma, offering improved survival outcomes with manageable toxicity. Further research is needed to refine patient selection and optimize treatment combinations.

Source: Journal of Pharmacy And Bioallied Sciences

DOI: 10.4103/jpbs.jpbs_1475_24